Junshi Biosciences Announces the Phase 3 Study of JS005 (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis Met Primary Endpoints
Notified -
Globe Newswire7-09-2025, 19:30
Peyto Reports Record Profit and Cash Flow in 2022 9-03-2023, 07:43